However elevated demand has led to shortages, and regulation of “copycat” GLP-1s and alternate options has created new challenges for telehealth companies coming into the weight-loss area. Financial uncertainty and cuts to Medicare and Medicaid are additionally creating new challenges in reaching shoppers.
“Organizations try to determine find out how to navigate the implications of that,” Beland stated. “Budgets are tight. Customers are extra discerning.”
Like many digital well being firms that scaled suring the pandemic, eMed launched in 2020 with COVID-19 testing and digital outcomes, however has struggled to search out affect since. It just lately pivoted into providing GLP-1 prescriptions for weight reduction.
eMed could also be coming into too late. Telehealth firms like Hims & Hers Well being and Ro rapidly capitalized on demand for GLP-1 medicine, and legacy manufacturers like WeightWatchers have launched marketplaces for weight-loss medicine, although a few of these have struggled to take off, Beland stated.
“It’s a much bigger phenomenon [but also a ] very turbulent advertising setting proper now,” he stated.
Source link
